Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 4
2004 10
2005 16
2006 8
2007 12
2008 14
2009 15
2010 4
2011 8
2012 8
2013 12
2014 4
2015 5
2016 5
2017 6
2018 18
2019 15
2020 21
2021 26
2022 17
2023 13
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

205 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.
Lorusso D, Xiang Y, Hasegawa K, Scambia G, Leiva M, Ramos-Elias P, Acevedo A, Sukhin V, Cloven N, Pereira de Santana Gomes AJ, Contreras Mejía F, Reiss A, Ayhan A, Lee JY, Saevets V, Zagouri F, Gilbert L, Sehouli J, Tharavichitkul E, Lindemann K, Lazzari R, Chang CL, Lampé R, Zhu H, Oaknin A, Christiaens M, Polterauer S, Usami T, Li K, Yamada K, Toker S, Keefe SM, Pignata S, Duska LR; ENGOT-cx11/GOG-3047/KEYNOTE-A18 investigators. Lorusso D, et al. Among authors: ayhan a. Lancet. 2024 Apr 6;403(10434):1341-1350. doi: 10.1016/S0140-6736(24)00317-9. Epub 2024 Mar 20. Lancet. 2024. PMID: 38521086 Clinical Trial.
ESGO statement on cervical cancer vaccination.
Vergote I, van der Zee AG, Kesic V, Sert B, Robova H, Rob L, Reed N, Luesley DM, Leblanc E, Hagen B, Gitsch G, du Bois A, di Vagno G, Colombo N, Beller U, Ayhan A, Jacobs I. Vergote I, et al. Among authors: ayhan a. Int J Gynecol Cancer. 2007 Nov-Dec;17(6):1183-5. doi: 10.1111/j.1525-1438.2007.01129.x. Int J Gynecol Cancer. 2007. PMID: 17997794 No abstract available.
Best original research presented at the 24th European Congress on Gynaecological Oncology-Best of ESGO 2023.
Kacperczyk-Bartnik J, Bizzarri N, Zwimpfer TA, El Hajj H, Angeles MA, Tóth R, Theofanakis C, Bilir E, Gasimli K, Strojna AN, Nikolova T, Ayhan A, Lorusso D, Chiva L. Kacperczyk-Bartnik J, et al. Among authors: ayhan a. Int J Gynecol Cancer. 2024 Apr 1;34(4):610-618. doi: 10.1136/ijgc-2023-005132. Int J Gynecol Cancer. 2024. PMID: 38088184 Review.
Post-recurrence survival in patients with cervical cancer.
Cibula D, Dostálek L, Jarkovsky J, Mom CH, Lopez A, Falconer H, Scambia G, Ayhan A, Kim SH, Isla Ortiz D, Klat J, Obermair A, Di Martino G, Pareja R, Manchanda R, Kosťun J, Dos Reis R, Meydanli MM, Odetto D, Laky R, Zapardiel I, Weinberger V, Benešová K, Borčinová M, Cardenas F, Wallin E, Pedone Anchora L, Akilli H, Abu-Rustum NR, Barquet-Muñoz SA, Javůrková V, Fischerová D, van Lonkhuijzen LRCW. Cibula D, et al. Among authors: ayhan a. Gynecol Oncol. 2022 Feb;164(2):362-369. doi: 10.1016/j.ygyno.2021.12.018. Epub 2021 Dec 23. Gynecol Oncol. 2022. PMID: 34955236 Free PMC article.
Nerve-sparing radical hysterectomy for cervical carcinoma.
Dursun P, Ayhan A, Kuscu E. Dursun P, et al. Among authors: ayhan a. Crit Rev Oncol Hematol. 2009 Jun;70(3):195-205. doi: 10.1016/j.critrevonc.2008.09.003. Epub 2008 Oct 15. Crit Rev Oncol Hematol. 2009. PMID: 18926716 Review.
Role of adjuvant therapy in intermediate-risk cervical cancer patients - Subanalyses of the SCCAN study.
Cibula D, Akilli H, Jarkovsky J, van Lonkhuijzen L, Scambia G, Meydanli MM, Ortiz DI, Falconer H, Abu-Rustum NR, Odetto D, Klát J, Dos Reis R, Zapardiel I, Di Martino G, Presl J, Laky R, López A, Weinberger V, Obermair A, Pareja R, Poncová R, Mom C, Bizzarri N, Borčinová M, Aslan K, Salcedo Hernandez RA, Fons G, Benešová K, Dostálek L, Ayhan A. Cibula D, et al. Among authors: ayhan a. Gynecol Oncol. 2023 Mar;170:195-202. doi: 10.1016/j.ygyno.2023.01.014. Epub 2023 Jan 25. Gynecol Oncol. 2023. PMID: 36706646 Free PMC article.
Learning Needs of Gynecologic Cancer Survivors.
Akkuzu G, Kurt G, Guvenc G, Kok G, Simsek S, Dogrusoy S, Ayhan A. Akkuzu G, et al. Among authors: ayhan a. J Cancer Educ. 2018 Jun;33(3):544-550. doi: 10.1007/s13187-016-1118-y. J Cancer Educ. 2018. PMID: 27743314
Emerging drugs in endometrial cancers.
Altundag O, Dursun P, Ayhan A. Altundag O, et al. Among authors: ayhan a. Expert Opin Emerg Drugs. 2010 Dec;15(4):557-68. doi: 10.1517/14728214.2010.517521. Epub 2010 Sep 9. Expert Opin Emerg Drugs. 2010. PMID: 20828226 Review.
A Turkish Gynecologic Oncology Group study of fertility-sparing treatment for early-stage endometrial cancer.
Dursun P, Erkanli S, Güzel AB, Gultekin M, Tarhan NC, Altundag O, Demirkiran F, Beşe T, Yildirim Y, Bozdag G, Yarali H, Simsek T, Ozcelik B, Ortaç F, Taskin S, Guvenal T, Ozgul N, Haberal A, Vardar MA, Dede M, Yenen M, Altintas A, Arvas M, Ayhan A. Dursun P, et al. Among authors: ayhan a. Int J Gynaecol Obstet. 2012 Dec;119(3):270-3. doi: 10.1016/j.ijgo.2012.06.010. Epub 2012 Aug 24. Int J Gynaecol Obstet. 2012. PMID: 22921272 Review.
205 results